147 related articles for article (PubMed ID: 7081915)
21. Early recurrence in breast cancer with efferent vascular invasion: a preliminary report.
Hartveit F; Støa KF; Tangen M
Invest Cell Pathol; 1980; 3(2):141-5. PubMed ID: 7380665
[TBL] [Abstract][Full Text] [Related]
22. Survival of women with node negative breast cancer in the Auckland region.
Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
24. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.
Sancak B; Coskun U; Gunel N; Onuk E; Cihan A; Karamercan A; Yildirim Y; Ozkan S
Intern Med J; 2004 Jun; 34(6):310-5. PubMed ID: 15228391
[TBL] [Abstract][Full Text] [Related]
25. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
Cherubini M; Baxa P; Guarino G
Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
[TBL] [Abstract][Full Text] [Related]
26. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
27. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Crabb SJ; Bajdik CD; Leung S; Speers CH; Kennecke H; Huntsman DG; Gelmon KA
Breast Cancer Res; 2008; 10(1):R6. PubMed ID: 18194560
[TBL] [Abstract][Full Text] [Related]
28. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology?
Mendez JE; Fey JV; Cody H; Borgen PI; Sclafani LM
Ann Surg Oncol; 2005 Jan; 12(1):24-8. PubMed ID: 15827774
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis.
Chen SL; Hoehne FM; Giuliano AE
Ann Surg Oncol; 2007 Dec; 14(12):3378-84. PubMed ID: 17899293
[TBL] [Abstract][Full Text] [Related]
30. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer].
Zhang S; Yuan Y; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Aug; 35(8):475-7. PubMed ID: 10678068
[TBL] [Abstract][Full Text] [Related]
31. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
33. Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases.
Sirvent JJ; Santafé M; Salvadó MT; Alvaro T; Raventós A; Palacios J
Histol Histopathol; 1994 Jul; 9(3):563-70. PubMed ID: 7526910
[TBL] [Abstract][Full Text] [Related]
34. Tumour size as a predictor of axillary node metastases in patients with breast cancer.
Laura S; Coombs NJ; Ung O; Boyages J
ANZ J Surg; 2006 Nov; 76(11):1002-6. PubMed ID: 17054550
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic factors in breast cancer--classification in non-university hospitals].
Willner J; Kiricuta IC; Kölbl O; Bohndorf W
Zentralbl Chir; 1993; 118(9):525-31. PubMed ID: 8237148
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
[TBL] [Abstract][Full Text] [Related]
37. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
Barth A; Craig PH; Silverstein MJ
Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.
Neri A; Marrelli D; Roviello F; De Stefano A; Guarnieri A; Pallucca E; Pinto E
Ann Surg Oncol; 2005 Mar; 12(3):246-53. PubMed ID: 15827817
[TBL] [Abstract][Full Text] [Related]
39. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer.
Saidi RF; Dudrick PS; Remine SG; Mittal VK
Am Surg; 2004 Feb; 70(2):101-5; discussion 105. PubMed ID: 15011910
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of intratumoural variations in elastosis grades and the oestrogen receptor status of human breast carcinomas.
Giri DD; Lonsdale RN; Dangerfield VJ; Harris SC; Parsons MA; Underwood JC
J Pathol; 1987 Apr; 151(4):297-303. PubMed ID: 3585588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
